Both in Biotechnology
Hemab Therapeutics Holdings vs Recursion Pharmaceuticals
Over the past year COAG returned +5.2% and RXRX returned +25.9%; their daily moves had a correlation of 0.29.
COAG +5.2% RXRX +25.9%Growth of $1, one year, split-adjusted
| Metric | COAG | RXRX |
|---|---|---|
| Price | $41.45 | $4.03 |
| Market cap | $1.94B | $2.41B |
| Today | +2.55% | −4.95% |
| 1 month | +33.5% | −1.0% |
| 6 months | — | +18.9% |
| Year to date | — | −1.5% |
| 1 year | — | −31.3% |
| Revenue growth (YoY) | — | −60.1% |
| Gross margin | — | −49.8% |
| Net margin | — | −1708.0% |
| P/E (TTM) | — | — |
| Price / sales | — | 43.9× |
| Net cash | $457.5M | $531.5M |
| Dividend yield | — | — |
| Volatility (60d) | — | 94.5% |
| Short % of float | 20.4% | 37.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).